Prolato Clinical Research Center | Houston, TX
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This study will evaluate the efficacy, safety, pharmacodynamics, and pharmacokinetics (PK) of obinutuzumab compared with tacrolimus in participants with primary membranous nephropathy (pMN).
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
140 participants in 2 patient groups
Loading...
Central trial contact
Reference Study ID Number: WA41937 https://forpatients.roche.com/
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal